索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]关硕,林飞,赵国安.预测经皮冠状动脉介入术后支架内再狭窄的新型生物标志物[J].国际心血管病杂志,2021,05:261-264.
点击复制

预测经皮冠状动脉介入术后支架内再狭窄的新型生物标志物(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年05期
页码:
261-264
栏目:
综述
出版日期:
2021-10-01

文章信息/Info

Title:
-
作者:
关硕;林飞;赵国安
453100 新乡医学院第一附属医院心脏中心,河南省心血管疾病临床数据与样本资源库工程研究中心
Author(s):
-
关键词:
再狭窄;  生物标志物;  代谢组学;  非编码RNA
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.05.002
文献标识码:
-
摘要:
支架内再狭窄(ISR)是经皮冠状动脉介入术(PCI)晚期失败的主要原因,严重影响预后,早期诊断ISR尤为重要。新型生物标志物具有早期预测ISR的潜力。代谢组学通过分析代谢产物、非编码RNA等指标反映病理过程,可预测早期ISR; 血细胞参数如红细胞分布宽度等可独立预测ISR的发生; 炎性反应相关生物标志物与ISR密切相关; 反映不同途径ISR进程的指标可分别预测术后血栓形成、新动脉粥样硬化和钙化进展以及老年人群ISR的发生。
Abstract:
-

参考文献/References

[1] Giacoppo D, Alfonso F, Xu B, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis[J]. J Am Coll Cardiol, 2020, 75(21):2664-2678.
[2] Kufner S, Joner M, Thannheimer A, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease[J]. Circulation, 2019, 139(3):325-333.
[3] Alfonso F, Byrne RA, Rivero FA, et al. Current treatment of in-stent restenosis[J]. J Am Coll Cardiol, 2014, 63(24):2659-2673.
[4] Dai T, Wang JR, Hu PF. Diagnostic performance of computed tomography angiography in the detection of coronary artery in-stent restenosis: evidence from an updated meta-analysis[J]. Eur Radiol, 2018, 28(4):1373-1382.
[5] Quyyumi AA, Samman TA, Jones DP. A small molecule solution to the vexing problem of restenosis: predicting restenosis[J]. JACC Cardiovasc Interv, 2017, 10(13):1317-1319.
[6] Cui S, Li K, Ang L, et al. Plasma phospholipids and sphingolipids identify stent restenosis after percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2017, 10(13):1307-1316.
[7] Jing XD, Wei XM, Deng SB, et al. The relationship between the high-density lipoprotein(HDL)-associated sphingosine-1-phosphate(S1P)and coronary in-stent restenosis[J]. Clin Chim Acta, 2015, 446: 248-252.
[8] De Rosa S, Eposito F, Carella C, et al. Transcoronary concentration gradients of circulating microRNAs in heart failure[J]. Eur J Heart Fail, 2018, 20(6):1000-1010.
[9] Jiang F, Zhang X, Lu YM, et al. Elevated level of miR-17 along with decreased levels of TIMP-1 and IL-6 in plasma associated with the risk of in-stent restenosis[J]. Biosci Trends, 2019, 13(5):423-429.
[10] Indolfi C, Iaconetti C, Gareri C, et al. Non-coding RNAs in vascular remodeling and restenosis[J]. Vascul Pharmacol, 2019, 114:49-63.
[11] Zhang J, Gao F, Ni T, et al. Linc-POU3F3 is overexpressed in in-stent restenosis patients and induces VSMC phenotypic transformation via POU3F3/miR-449a/KLF4 signaling pathway[J]. Am J Transl Res, 2019, 11(7):4481-4490.
[12] Fang W, Xi S, Liu CW, et al. Prognostic value of plasma long noncoding RNA ANRIL for in-stent restenosis[J]. Medical Science Monitor, 2017, 23:4733-4739.
[13] He M, Gong Y, Shi J, et al. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis[J]. PLoS One, 2014, 9(11):e112043.
[14] Saavedra N, Rojas G, Herrera J, et al. Circulating miRNA-23b and miRNA-143 are potential biomarkers for in-stent restenosis[J]. Biomed Res Int, 2020:2509039.
[15] Yuan Y, Liu X, Hao S, et al. Plasma levels of miR-143 and miR-145 are associated with coronary in-stent restenosis within 1 year of follow-up after drug-eluting stent implantation[J]. Ann Transl Med, 2020, 8(12):756.
[16] Li N, Zhou H, Tang Q. Red blood cell distribution width: a novel predictive indicator for cardiovascular and cerebrovascular diseases[J]. Dis Markers, 2017:7089493.
[17] Qian H, Luo Z, Xiao C, et al. Red cell distribution width in coronary heart disease prediction of restenosis and its relationship with inflammatory markers and lipids[J]. Postgrad Med J, 2018, 94(1115):489-494.
[18] Zhao K, Li Y, Jin Z, et al. The association of red blood cell distribution width with drug-eluting stent restenosis in unstable angina pectoris patients[J]. Int J Cardiol, 2015, 191:1-3.
[19] Ucar FM. A potential marker of bare metal stent restenosis: monocyte count-to-HDL cholesterol ratio[J]. BMC Cardiovasc Disord, 2016, 16(1):186.
[20] Celik T, Iyisoy A, Barindik N, et al. Glucocorticoids in the prevention of in-stent restenosis: the role of inflammation[J]. Int J Cardiol, 2009, 135(3):403-405.
[21] Drachman DE, Simon DI. Inflammation as a mechanism and therapeutic target for in-stent restenosis[J]. Curr Atheroscler Rep, 2005, 7(1):44-49.
[22] Liang S, Aiqun M, Jiwu L, et al. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients[J]. Immunol Res, 2016, 64(2):424-430.
[23] Jiang H, Liu W, Liu Y, et al. High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis[J]. Anatol J Cardiol, 2015, 15(11):907-912.
[24] Küp A, Toprak C, Bayam E, et al. Serum endocan levels predict drug-eluting stent restenosis in patients with stable angina pectoris[J]. Acta Cardiol Sin, 2020, 36(2):111-117.
[25] Liang H, Cui Y, Bu H, et al. Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation[J]. Exp Ther Med, 2020, 20(1):211-218.
[26] Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis[J]. Circulation, 2002, 105(9):1135-1143.
[27] Bliden KP, Tantry US, Gesheff MG, et al. Thrombin-induced platelet-fibrin clot strength identified by thrombelastography: a novel prothrombotic marker of coronary artery stent restenosis[J]. J Interv Cardiol, 2016, 29(2):168-178.
[28] Huang WC, Teng HI, Chen HY, et al. Association between asymmetric dimethylarginine and in-stent restenosis tissue characteristics assessed by optical coherence tomography[J]. Int J Cardiol, 2019, 289:131-137.
[29] Pleva L, Kusnierova P, Plevova P, et al. Increased levels of MMP-3, MMP-9 and MPO represent predictors of in-stent restenosis, while increased levels of ADMA, LCAT, ApoE and ApoD predict bare metal stent patency[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015, 159(4):586-594.
[30] Li X, Zhang F, Zhou H, et al. Potential prognostic, diagnostic and therapeutic markers for in-stent reocclusion in advanced age patients after coronary stenting[J]. Curr Pharm Des, 2018, 24(28):3359-3365.

备注/Memo

备注/Memo:
通信作者:赵国安,E-mail:guoanzhao@xxmu.edu.cn
更新日期/Last Update: 2021-10-01